Jamunarani Veeraraghavan

3PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.

Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis

|May 28, 2021
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.

Jamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath

|Dec 15, 2019
Towards personalized treatment for early stage HER2-positive breast cancer.

Kristina Goutsouliak, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath

Pageof 1